• Adam S Fleisher, Rema Raman, Eric R Siemers, Lida Becerra, Christopher M Clark, Robert A Dean, Martin R Farlow, James E Galvin, Elaine R Peskind, Joseph F Quinn, Abdullah Sherzai, B Brooke Sowell, Paul S Aisen, and Leon J Thal.
• University of California, San Diego, La Jolla, CA 92037, USA. afleisher@ucsd.edu
• Arch. Neurol. 2008 Aug 1;65(8):1031-8.

ObjectiveTo evaluate the safety, tolerability, and amyloid beta (Abeta) response to the gamma-secretase inhibitor LY450139 in Alzheimer disease.DesignMulticenter, randomized, double-blind, dose-escalation, placebo-controlled trial.SettingCommunity-based clinical research centers. Patients Fifty-one individuals with mild to moderate Alzheimer disease were randomized to receive placebo (n=15) or LY450139 (100 mg [n=22] or 140 mg [n=14]), with 43 completing the treatment phase. Intervention The LY450139 groups received 60 mg/d for 2 weeks, then 100 mg/d for 6 weeks, and then either 100 or 140 mg/d for 6 additional weeks.Main Outcome MeasuresPrimary outcome measures were adverse events, plasma and cerebrospinal fluid Abeta levels, vital signs, electrocardiographic data, and laboratory safety test results. Secondary outcome measures included the Alzheimer's Disease Assessment Scale cognitive subscale and the Alzheimer's Disease Cooperative Study Activities of Daily Living Scale.ResultsGroup differences were seen in skin and subcutaneous tissue concerns (P=.05), including 3 possible drug rashes and 3 reports of hair color change in the treatment groups. There were 3 adverse event-related discontinuations, including 1 transient bowel obstruction. The plasma Abeta(40) concentration was reduced by 58.2% for the 100-mg group and 64.6% for the 140-mg group (P<.001). No significant reduction was seen in cerebrospinal fluid Abeta levels. No group differences were seen in cognitive or functional measures.ConclusionsLY450139 was generally well tolerated at doses of up to 140 mg/d for 14 weeks, with several findings indicating the need for close clinical monitoring in future studies. Decreases in plasma Abeta concentrations were consistent with inhibition of gamma-secretase. Trial Registration clinicaltrials.gov Identifier: NCT00244322.

37 keywords...

hide…